Genotyping, Other Clinical Variables May Predict Everolimus Treatment Effects
the Cancer Therapy Advisor take:
The PI3KCA gene polymorphism, lactate dehydrogenase (LDH), and histologic grade can predict the effects of everolimus treatment, while corrected calcium level and a PIK3CA gene variant may be independent prognostic factors in patients with metastatic renal cell carcinoma, a new study published online in the journal Annals of Oncology has shown.
For the prospective, single-arm, phase II trial, researchers sought to identify predictive and prognostic factors in patients with metastatic renal cell carcinoma treated with everolimus 10mg daily. Specifically, they evaluated potential biomarkers of the PI3K/AKT/mTOR pathway.
Results showed that histological grade G1/2 (HR = 2.68; 95% CI: 1.29-5.58; P = 0.0082), increased LDH before treatment (HR = 2.55; 95% CI: 1.30-4.99; P = 0.0064), and the PIK3CA gene variant rs6443624 (HR = 2.08; 95% CI: 1.11-3.89; P = 0.0254) were adverse independent predictors for everolimus treatment.
Researchers also found that elevated corrected calcium level (HR = 4.17; 95% CI: 1.66-10.51; P = 0.0024) and the PIK3CA gene variant rs6443624 (HR = 1.97; 95% CI: 1.02-3.79; P = 0.0421) may be independent prognostic factors.
The authors note that further prospective studies are warranted to confirm and validate these findings.

Genotyping can predict the effects of everolimus treatment in patients with metastatic renal cell carcinoma.
Related Resources
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma